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Abstract
Background: Statistical methods to tentatively identify differentially expressed genes in microarray studies typically
assume larger sample sizes than are practical or even possible in some settings.
Results: The performance of several probe-level and probeset models was assessed graphically and numerically
using three spike-in datasets. Based on the Affymetrix GeneChip, a novel nested factorial model was developed
and found to perform competitively on small-sample spike-in experiments.
Conclusions: Statistical methods with test statistics related to the estimated log fold change tend to be more
consistent in their performance on small-sample gene expression data. For such small-sample experiments, the
nested factorial model can be a useful statistical tool. This method is implemented in freely-available R code
(affyNFM), available with a tutorial document at http://www.stat.usu.edu/~jrstevens.
Background
Introduction
Over the past decade, gene expression microarray tech-
nology [1] has become a relatively common tool in the
biological sciences. A traditional application of this tech-
nology is to measure gene expression in two or more
groups of individuals that differ according to some char-
acteristic of interest, and then to identify genes whose
expression levels change systematically between groups.
An ongoing collaboration with the J. R. Simplot Com-
pany involves the cloning of cattle using nuclear transfer
(NT). Published results include an evaluation of the dif-
ferences in NT success rates using cow vs. heifer
oocytes [2] and an evaluation of the effects of various
time intervals between fusion and activation on the
development of bovine NT pregnancies [3]. Recently,
microarray technology has been employed in this colla-
boration, in particular examining the gene expression
differences between NT and control (non-NT) samples
at various stages of the NT cloning process [4]. One
goal of the microarray application in this work is to
identify a potential genetic basis for successful NT preg-
nancies, as well as a potential genetic basis for NT fail-
ure. Once understood, this genetic basis can be used to
achieve a greater success rate in NT pregnancies, so
that attributes such as carcass quality can be maximized
and preserved in successive generations of cattle.
Because of the high cost in time and money for NT
and gene expression studies, the high level of work
necessary to perform NT, and the difficulty in achiev-
ing successful bovine NT pregnancies, the sample sizes
in these microarray experiments tend to be quite low.
While many biomedical applications currently involve
dozens of samples, the microarray work done thus far
with bovine NT studies has been limited to six to
eight samples for each comparison. Much of the statis-
tical methodology that has been developed for micro-
array data analysis over the past decade [5] has been
driven by medical applications such as human cancer
research, where samples are much more abundant. As
a result, the most common statistical models assume a
larger sample size than has been practical in the
bovine NT work.
This study evaluates alternative statistical models in an
effort to identify appropriate approaches for microarray
experiments with small sample sizes. The Results and
Discussion section consists of a summary of these meth-
ods, including a novel presentation of our probe-level
nested factorial model, and a discussion of the relative
performance of these methods on spike-in data. * Correspondence: john.r.stevens@usu.edu
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The relative performance of competing statistical meth-
ods can be assessed using spike-in data, and the most
promising method was applied to the bovine NT data.
For this study, all data considered are of a simple treat-
ment vs. control design.
The motivating bovine NT dataset, mentioned in the
Introduction subsection, was taken from an experiment
in the cloning of cattle (NT). Tissue samples were taken
and prepared from cotyledon (part of the uterine side of
the placenta) in an impregnated cow. Four of these
pregnancies involved NT and three were control, mak-
ing 7 total arrays. For these data, we are interested in
identifying genes that behave differently in the NT sam-
ples than in the non-NT samples. The Affymetrix
bovine array was used, with 24,128 probesets.
In spike-in microarray experiments, the “truth” is
known a priori. In particular, genes whose mRNA has
been artificially increased in a sample to be hybridized
onto the array are said to be “spiked-in.” The “expres-
sion levels” of these genes can be controlled by modify-
ing their spike-in concentrations. Thus their “expression
levels” can be made to change across “treatments.” That
is, they are known to be differentially expressed. Hence
it can be verified how well statistical models identify dif-
ferentially expressed genes in general by how well they
find spiked-in genes in these types of experiments.
Data from three spike-in experiments were used to
compare the different statistical models. The Affymetrix
HGU95A spike-in data [6] consist of 59 arrays and
12,626 probesets on each array, out of which 14 probe-
sets were spiked-in. For this small-sample study, only 8
arrays were used, corresponding to groups M-T of wafer
1532 of the spike-in data, with 4 control and 4 treat-
ment arrays.
The Affymetrix HGU133A spike-in data [6] consist of
42 arrays and 22,300 probesets on each array, out of
which 42 probesets were originally spiked-in, with 3
more probesets known to contain probes exactly match-
ing the spiked sequences. Subsequent work [7] identified
22 additional spike-in probesets, but the inclusion of
t h e s ea d d i t i o n a l2 2d i dn o ts u b s t a n t i a l l yc h a n g et h e
results of our study. We considered the HGU133A
experiment as having 45 spiked-in probesets. For this
small-sample study, only 6 arrays were used, corre-
sponding to experiments 5 and 6 of the spike-in data,
with 3 control and 3 treatment arrays.
The third and final spike-in dataset used was the
“Golden Spike” dataset [8]. There has been some ques-
tion regarding the credibility of this experiment [9,10].
Specifically, the dataset uses potentially unrealistically
high levels of spike-in concentration, and the spike-ins
are all up-regulated in the treatment group relative to
the control group. However, it is still sometimes used as
a tool in comparing statistical models, and we include it
here for discussion. This experiment consists of 6 arrays
(3 control, 3 treatment), with 1,331 of 14,010 probesets
spiked-in.
Results and Discussion
Algorithm
The Affymetrix GeneChip is among the most commonly
used microarray platforms, and typically represents each
gene on the array as a set of 11-20 probes, called a pro-
beset. Preprocessing methods such as RMA [11] com-
bine probe-level intensities to give an expression
estimate of each gene in each sample of the experiment.
Our initial hypothesis in this study was that using only
preprocessed data in assessing differential expression
does not take full advantage of available information at
the probe level and could be improved. This loss of
information seems especially concerning in cases such
as the motivating bovine NT study, where there are a
relatively small number of samples. Probe-level models
for differential expression provide a possible alternative,
without this loss of information.
The purpose of this study was to compare several
probe-level models with one of the most popular probe-
set models. In this section, we summarize the
approaches of several methods (both probeset and
probe-level) to calculate test statistics for evaluating dif-
ferential expression. Unless otherwise stated, RMA pre-
processing [11] was done prior to all probeset models,
and prior to all probe-level models, the background cor-
rection and quantile normalization steps of RMA were
performed. (As an alternative, GCRMA preprocessing
[12] was done prior to all probeset models, and prior to
all probe-level models, GCRMA background correction
[12] followed by quantile normalization was performed.)
All analyses were conducted in R [13], making use of
several packages in Bioconductor [14].
NFM
A nested factorial model (NFM) is a basic structure in
experimental design and is developed and presented for
the first time in this work with application to microarray
data. For each gene k we have the model:
YT S P T P S P ijl i ji l il jl i =++ ++ () + () () ()  . (1)
Yijl is the background-corrected quantile-normalized
log-scale perfect match intensity for probe l of the
gene on array j under treatment level i, Ti is the treat-
ment effect, Sj(i) is the subject (or array) effect nested
within treatment, Pl is the probe effect, (TP)il is an
interaction between treatment and probe, and (SP)jl(i)
is used as the error term. This model clearly takes into
account any probe information that may be lost in a
probeset model.
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each gene is differentially expressed between treatment
levels, we are testing H0: T1 = T2, and we can look at an
F-statistic for the treatment effect. This statistic can be
obtained via restricted maximum likelihood (REML)
estimation, as implemented in the lme function of the
nlme R package [15,16].
It is important to note that, due to the nature of the
nested design, an iterative process (REML) is necessary
to obtain the F-statistic for each gene. This iterative pro-
cess takes some time and can be very slow when there is
a very large number of factor levels, such as a large
number of probes per gene on some array types (as in
tiling arrays).
PLM
Bolstad (2004) suggested a probe-level model [17],
referred to here as PLM. To assess differential expres-
sion across treatments, the per-gene model:
Ylj l j lj =++  (2)
is used, where Ylj is the background-corrected quantile-
normalized log-scale perfect match intensity for probe l
of the gene on array j, al is the probe effect, and bj is the
array effect. This model is fit using the fitPLM function
of the affyPLM R package [17]. Bolstad (2004) defines
two test statistics to evaluate differential expression:
t
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Here, 
∧ is a vector of estimated array effects and Σ is
the portion of the estimated variance/covariance matrix
corresponding to 
∧ . The length of vector c is the total
number of arrays in the dataset. The elements of c
depend on how many arrays are in each treatment level.
F o ras i m p l et w o - g r o u pd e s i g n ,e l e m e n tj of c is 1
1 n if
array j is in treatment group 1, − 1
2 n if array j is in
treatment group 2, and 0 otherwise, where ni is the
number of samples in treatment group i.T h e nc’ 
∧ is
the log fold change across treatments. PLM is a very
fast process since it involves nothing more than some
matrix computations, which are very efficient in R.
LE
Limma/eBayes (LE) is a very popular probeset-level
method in which a hierarchical Bayes model is used to
define a moderated test statistic for assessing differential
expression [18]. First, we assume a linear model for
each gene k:
YT ijk k k i ijk =+ +   ,, . 01 (5)
Here, Yijk is the log-scale expression level for gene k
on array j in treatment group i, and bk,1 is the treatment
effect. Ti is the treatment level of the array, coded as a
dummy variable (here, 0 for control and 1 for treat-
ment). The εijk is an error term with Var(εijk)= k
2.
Estimates 
∧
k , 
∧
k
2 and Var( 
∧
k )=Vk are obtained via
traditional least squares principles. The traditional t-test
statistic for assessing the treatment effect (H0: bk,1 = 0) is:
t k
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,
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11
(6)
Here, Vk11 , is the element of Vk corresponding to the
variance of bk,1. Under this H0, tk follows a t-distribution
with degrees of freedom dk.
One limitation of this traditional t-test statistic is the
reliability of the estimate 
∧
k
2.I ti si n t e n d e dt oe s t i m a t e
the amount of variability expected in the gene’se x p r e s -
sion levels for all possible samples in a single group
(treatment, for example). The small sample sizes some-
times seen in microarray experiments affect the reliabil-
ity of this estimate, and several statistical models have
proposed modified estimates, some of which seek to
pool information across genes. The limma/eBayes pool-
ing approach is to assume a prior distribution on the
precision:
1
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all genes) with empirical Bayes methods. The posterior
mean:
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is used as an updated estimate of the variability  k
2.
With this, a moderated t-statistic for each gene k is:

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of freedom d0 + dk . LE is a very efficient method in the
sense that it runs as fast as PLM. The LE method is
implemented in the R package limma [18].
PLLM
Lemieux (2006) proposed a probe-level linear model
(PLLM) [19]. It uses a linear model to estimate the
treatment effect directly, using information at the probe
level. The PLLM approach begins with the simple
model:
YT ijl l i ijl =++  (10)
for each gene k,w h e r eYijl is as defined following
Equation 1, al is a combination of the expression level
of the gene across arrays and specific probe affinities,
and Ti is the effect of treatment level i. The treatment
effect is estimated using standard least-square proce-
dures. We plot these against the average log probeset
intensities to reveal a Gaussian mixture model, as in Fig-
ure 1. The original PLLM paper [19] used the Golden
Spike data, and Figure 1c shows three clusters of points
for these data, one of which appears to coincide with
the spike-in probesets.
To fit the Gaussian mixture, after using such plots to
decide the number of components to include, we used
the implementation in the R package mclust [20]. To
test for differential expression, we use as the test statis-
tic the conditional probability that the gene belongs to
the most extreme cluster (in terms of the absolute treat-
ment effect) from the Gaussian mixture model.
One drawback to this model is that it can not be auto-
mated. One has to manually choose the number of com-
ponents to use in the Gaussian mixture model by
looking at these plots. It is not always clear how many
components to choose for the mixture model (see
Figure 1ab). Based on recommendations from Lemieux
(personal communication), anywhere in the order of 5-
15 components seems reasonable.
PLW
The probe-level locally moderated weighted median-t
method (PLW) uses a hierarchical Bayes model to
obtain a moderated, weighted t-statistic for each PM
probe [21,22]. With the background-corrected, quantile-
normalized data, a weighted, moderated test statistic is
calculated for each probe. The test statistic for whether
or not gene k is differentially expressed is then calcu-
lated by taking the median of the moderated test statis-
tics for each probe within gene k. This method has been
implemented in the R package plw [21,22].
FC
For purposes of comparison, the naive fold change (FC)
across treatments is also considered as a test statistic in
identifying differentially expressed genes. For this study,
the (log) fold change was calculated as the numerator of
Equation 3, i.e., c’ 
∧ ,w h e r ec and 
∧ are as previously
described in the PLM discussion.
RMANOVA
The robustified MANOVA (RMANOVA) approach is a
probe-level model based on the framework of multivari-
ate analysis of variance [23], fit on a per-gene basis. For
ag i v e ng e n e ,l e tyj(i) be the vector of background-cor-
rected quantile-normalized log-scale perfect match
intensities on array j within treatment level i. For treat-
ment level i,l e tμ(i) represent the corresponding vector
of expected values for treatment level i. Similarly, let μ
be the corresponding vector of expected values across
all treatment levels. In the two-treatment case (of inter-
est here), the null hypothesis of interest is H0: μ(1) = μ(2).
Let the vector   i ()be a robust estimate of μ(i),
obtained by taking the component-wise median across
Figure 1 Gaussian mixture model from PLLM. The plot of average intensity vs. treatment effect as estimated in the PLLM approach is used to
identify underlying components in a Gaussian mixture model. The blue points correspond to the known spiked-in genes in each of the three
datasets. The Golden Spike dataset has three main components, with one predominantly corresponding to the spiked-in genes. In the other
datasets the components are not as clear.
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estimate of μ, obtained by taking the component-wise
median across all yj(i) for all treatment levels. Let ni be
the number of arrays in treatment level i. Then the
within-treatment and between-treatment error matrices
are estimated respectively as:
W ny y i j ji i ji i
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Here the sum and median are applied component-
wise.
Two test statistics are proposed by Xu and Cui (2008)
[ 2 3 ] ,r e f e r r e dt oh e r ea sR M A N O V A 1a n dR M A -
NOVA2, respectively:
G
G B
=
= ()
()
trB
~
trW
~
median diag
median diagW
,
~ ~
~ .
(13)
Here again the median is applied component-wise.
Both of these test statistics are constructed with the
same philosophy of the F-statistic in a one-way ANOVA
model, as the ratio of between-treatment to within-
treatment error. However, unlike the ANOVA F-statis-
tic, the numerators of these test statistics are not
directly related to the log fold change. Still, larger test
statistics are taken as greater evidence of differential
expression. Xu and Cui (2008) [23] provide Matlab
functions for this method, but we use a custom R imple-
mentation for convenience in comparison.
FIRSTP
Rubin (2009) proposed a “first principles” (FIRSTP)
probe-level approach to testing for differential expres-
sion [24]. For a given gene, let Yijl be the background-
corrected quantile-normalized log-scale perfect match
intensity for probe l o ft h eg e n eo na r r a yj under treat-
ment level i. For each probe l of the gene, the FIRSTP
approach is based on the simple model:
YT ijl l i l ijl =+ +  , , (14)
where μl is the population mean for probe l,a n dTi, l
is the effect of treatment level i for probe l. Using tradi-
tional parametric ANOVAm e t h o d s ,ap - v a l u e( pl)i s
obtained for the null hypothesis H0: T1, l = T2, l,f o r
each probe l of the gene. (We encountered undefined pl
values for the occasional probes where the Y values
were the same on all arrays. This was more common
with very small numbers of arrays. Our strategy was to
reset these pl values to 1 to represent no evidence of dif-
ferential expression of the probe.)
For the overall test of differential expression for the
gene, the test statistic for the gene is the median (over
all probes l)o f1-p l. Larger values of the test statistic
are indicative of greater evidence of differential expres-
sion. This FIRSTP approach is similar in spirit to the
PLW method (because both utilize medians of probe-
level test statistics), but differs in that the “first princi-
ples” philosophy limits the number of assumptions and
model components. We used a custom R implementa-
tion of this FIRSTP method.
PUMA
Propagating Uncertainty in Microarray Analysis, or
PUMA, accounts for uncertainty of the measured value
of each gene when doing these experiments, and
includes a probe-specific parameter in a probabilistic
model [25-27]. The model accounts for information
from both the perfect match (PM) and mismatch (MM)
probes, instead of treating MM probes as background.
The first step of PUMA is to preprocess the raw
microarray data using a method called multi-chip modi-
fied gamma Model for Oligonucleotide Signal, or multi-
mgMOS. This method uses a hierarchical Bayes model
to obtain the expression level for each gene.
After this preprocessing, PUMA uses a hierarchical
model to obtain the posterior distribution on μi,t h e
mean expression value of a gene for treatment level i.
Since this posterior distribution cannot be written in
closed form, an EM algorithm (using MCMC) is used to
approximate the distribution. The test statistic for each
gene is then the probability that the gene is up-regulated
(or down-regulated); i.e., the probability that μ1 >μ2 (or
μ2 >μ1), is then calculated. These test statistics can be
converted into a “p-like-value,” which is the probability
that each gene is differentially expressed. The p-like-
v a l u e sa r em o r ec o m p a r a b l et ot h ep - v a l u e sr e t u r n e d
from other methods, in that smaller values represent
stronger evidence of differential expression. These meth-
ods have been implemented in the R package puma [28].
Testing
In order to understand how well each of the previously
defined statistical models can identify differentially
expressed genes, each was compared simultaneously by
considering the true positive rate (TPR) and the false
positive rate (FPR) in the three spike-in datasets
described previously. For each model, a test statistic was
obtained for each gene and the absolute values of these
test statistics were sorted in increasing order. The TPR
Stevens et al. BMC Bioinformatics 2010, 11:281
http://www.biomedcentral.com/1471-2105/11/281
Page 5 of 17and FPR values were defined as in Bolstad (2004) [17]:
For the entire set of sorted test statistics, count the
number of spike-in genes that are called significant (i.e.
that are in the set being considered) and divide that by
the total number of spike-in genes. Call that the TPR
for the first set of sorted test statistics. Count the num-
ber of non-spike-in genes called significant and divide
that by the total number of genes that are not spiked-in.
Call this the FPR for the first set of sorted test statistics.
Then omit the test statistic with the smallest absolute
value and obtain a TPR and FPR for that subset of test
statistics. Repeat this process by removing the test statis-
tic with the smallest absolute value each time, obtaining
TPRs and FPRs for each subset of test statistics. For the
last iteration, the subset will only contain one test statis-
tic. The total number of TPR and FPR values obtained
will be equal to the total number of genes in the dataset.
For each spike-in dataset, a receiver operating charac-
teristic (ROC) curve was created to visually assess how
well each model performed. The ROC curve is a plot of
TPR vs. FPR. A higher curve indicates higher perfor-
mance in identifying differentially expressed genes.
“Higher” here can be assessed both graphically (with the
ROC curve) and numerically (with the AUC, or area
under the ROC curve).
Because our focus is performance in small-sample stu-
dies, we also looked at subsets of the spike-in studies.
For example, the HGU95A dataset has four arrays in
each of two treatments. In addition to this 4 × 4 com-
parison, we also tested for differential expression in all
16 3 × 3 and all 36 2 × 2 comparisons. For each method
fit, the TPR and FPR were averaged across all 16 3 × 3
comparisons, and separately averaged across all 36 2 × 2
comparisons. The HGU133A and Golden Spike datasets
both have three arrays in each of two treatments. In
addition to their 3 × 3 comparisons, we averaged the
T P Ra n dF P Ra c r o s st h e i rr e s p e c t i v e92×2
comparisons.
Results
Figure 2 and Table 1 summarize the performance of the
various methods on all three spike-in data sets plus the
average performance across their subsets, using RMA
preprocessing [11] for all methods, except for PUMA,
which relies on multi-mgMOS preprocessing [25-27].
Figure 3 “zooms in” on the same ROC curves to focus
on performance at lower false positive rates (FPR). For
methods with higher ROC curves at low FPR, the genes
at the top of their ranked lists (by test statistic) are
more likely to be the truly differentially expressed genes
than are those at the top of the other methods’ ranked
lists.
Figure 4 and Table 2 summarize the performance of
the various methods on all three spike-in data sets plus
the average performance across their subsets, using
GCRMA preprocessing [12] for all methods, except for
PUMA, which relies on multi-mgMOS preprocessing
[25-27]. Figure 5 “zooms in” on the same ROC curves
to focus on performance at lower false positive rates
(FPR).
The NFM method is consistently among the top per-
formers at low FPR, except in the Golden Spike data.
( T h ep o o r e rp e r f o r m a n c ei nt h eG o l d e nS p i k ed a t ai s
examined in the two following paragraphs.) The PLM
methods perform well in the HGU95A data, and are
among the best at low FPR for the Golden Spike data
with GCRMA preprocessing. The LE method has a
slightly variable performance, doing well in the
HGU95A data, and among the best at low FPR for the
HGU133A data with RMA preprocessing, but among
the worst at low FPR for the HGU133A data with
GCRMA preprocessing. The PLLM method is more
variable, as it is clearly the best performer on the
Golden Spike data with RMA preprocessing, and
among the best at low FPR on the HGU133A data
with GCRMA preprocessing, but among the worst at
low FPR for the Golden Spike data with GCRMA pre-
processing. The PLW method is among the best for
the Golden Spike data with GCRMA preprocessing,
and at low FPR for the HGU133A data with GCRMA
preprocessing. The FC method is among the best for
the Golden Spike data with GCRMA preprocessing
and at low FPR for the HGU133A data with RMA pre-
processing, but among the worst at low FPR for sub-
sets of the HGU95A and HGU133A data with
G C R M Ap r e p r o c e s s i n g .R M A N O V At e n d st ob e
among the lowest performers, but gives the best overall
performance on the HGU133A data with RMA prepro-
cessing (and even there, it is a low performer at low
FPR). The FIRSTP method gives a variable perfor-
mance, and is never the best or worst overall. PUMA
is the top overall performer on the HGU133A data
with GCRMA preprocessing, but there (and consis-
tently in the other data sets) it is among the low per-
formers at low FPR.
Because the Golden Spike data have large numbers
o fg e n e ss p i k e di na te a c ho fs e v e r a lk n o w nf o l d
changes, the performance of these statistical methods
can be compared in identifying the spiked-in genes by
fold change. Figure 6 summarizes the performance of
the various methods on the full 3 × 3 Golden Spike
comparison with RMA preprocessing, for identifying
genes spiked-in at different fold-changes. There appear
to be four levels of performance on the Golden Spike
data - PLLM is generally superior for all fold-changes
except 1.2 (and this superiority may be attributable to
the unique pattern observed in Figure 1c), PUMA per-
forms worse for larger fold-changes, RMANOVA per-
forms poorly in general (with improvement for larger
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roughly similarly (with noticeably poorer performance
at fold-changes 1.5 and 1.7). Figure 7 considers these
four levels of performance, with NFM and PLW as
examples of the final level. The distributions of overall
ranks of test statistics within each method are com-
pared based on the spiked-in fold-changes. While
PLLM and PUMA show an overall drop in ranks for
higher fold changes, the expected overall increase in
r a n k sf o rh i g h e rf o l dc h a n g e si so b s e r v e df o rR M A -
N O V A ,N F M ,a n dP L W .
The methods comprising this fourth level of perfor-
mance (NFM, PLM, LE, PLW, FC, and FIRSTP) all
share a common characteristic, that their test statistics
are related to the simple estimated log fold change.
This is due to their being based on traditional
Figure 2 ROC curves for RMA-preprocessed data. With RMA preprocessing, the performance of several methods testing for differential
expression is compared using (a) the full 4 × 4 comparison of the HGU95A spike-in data, as well as the averages across (b) all 3 × 3 and (c) all
2 × 2 subsets. The methods are also compared using (d) the full 3 × 3 and (e) the average of all 2 × 2 comparisons of the HGU133A spike-in
data, as well as using (f) the full 3 × 3 and (g) the average of all 2 × 2 comparisons of the Golden Spike spike-in data.
Table 1 Area Under Curve (AUC) values for each model
on each data subset, using RMA preprocessing.
HGU95A HGU133A Golden Spike
4×4 3×3 s 2×2 s 3×3 2×2 s 3×3 2×2 s
NFM 0.9993 0.9987 0.9922 0.9510 0.9488 0.7611 0.7568
PLM1 0.9982 0.9961 0.9896 0.9447 0.9471 0.8009 0.7977
PLM2 0.9982 0.9961 0.9895 0.9447 0.9470 0.8009 0.7977
LE 0.9985 0.9941 0.9817 0.9597 0.9397 0.7658 0.7600
PL-LM 0.9982 0.9952 0.9864 0.9168 0.9110 0.9619 0.9553
PLW 0.9982 0.9906 0.9854 0.9466 0.9375 0.8208 0.8138
FC 0.9953 0.9891 0.9764 0.9571 0.9403 0.7679 0.7622
RMANOVA1 0.6638 0.5854 0.5320 0.9665 0.9413 0.4142 0.3816
RMANOVA2 0.6935 0.6492 0.5885 0.9713 0.9580 0.4922 0.4577
FIRSTP 0.9753 0.9660 0.9553 0.9409 0.9244 0.7983 0.7746
PUMA 0.9435 0.9276 0.9019 0.9133 0.9143 0.7901 0.7769
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Page 7 of 17ANOVA-type models. (The PLLM method begins with
the ANOVA-type model in Equation 10, but the test
statistic is actually based on the result of the subse-
quent Gaussian mixture model.) When this estimated
log fold change is low, the test statistics for these
methods tend to be lower. This is what caused these
methods’ performance to drop in the Golden Spike
data at fold-changes 1.5 and 1.7. Figure 7f shows that
at these fold-changes, the estimated log fold changes
were noticeably and systematically lower.
Implementation
All Methods - Bovine NT Application
All probe-level and probeset-level methods discussed
previously were applied to the motivating bovine NT
data, with RMA preprocessing for the non-PUMA
methods. The top 500 genes (based on ranked test
statistics) from each method were identified, with a
u n i o no f2 , 4 3 2g e n e sa c r o s st h em e t h o d s .T h eo v e r a l l
ranks of these 2,432 genes within each method were
used to compare the results of each method while
Figure 3 Partial ROC curves for RMA-preprocessed data. (a-h) Partial ROC curves from Figure 2 to focus on portions of greatest interest -
low false positive and high true positive rates. Note that the vertical axes in (f) and (g) are on the log scale to facilitate visualization. The same
color legend of Figure 2 applies here.
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Page 8 of 17allowing for scale differences between test statistics
from each method. Figure 8a visualizes the agglomera-
tive nesting clustering of the methods (based on over-
all ranks of these 2,432 genes), using Manhattan
distance with average linkage. The biplot in Figure 8b
visualizes the first two principal components for these
ranks of test statistics within method. This principal
components analysis made use of the princomp2
function in the msProcess R package [29], allowing for
“wide” data such as this, where the number of genes
far exceeds the number of methods. Figure 8 supports
what was seen in Figures 6 and 7, that in terms of
ranking genes, the PUMA, RMANOVA, and
PLLM approaches each stand apart as performing
quite differently from the other fold-change-based
methods.
Figure 4 ROC curves for GCRMA-preprocessed data. With GCRMA preprocessing, the performance of several methods testing for differential
expression is compared using (a) the full 4 × 4 comparison of the HGU95A spike-in data, as well as the averages across (b) all 3 × 3 and (c) all
2 × 2 subsets. The methods are also compared using (d) the full 3 × 3 and (e) the average of all 2 × 2 comparisons of the HGU133A spike-in
data, as well as using (f) the full 3 × 3 and (g) the average of all 2 × 2 comparisons of the Golden Spike spike-in data.
Table 2 Area Under Curve (AUC) values for each model
on each data subset, using GCRMA preprocessing.
HGU95A HGU133A Golden Spike
4×4 3×3 s 2×2 s 3×3 2×2 s 3×3 2×2 s
NFM 0.9991 0.9979 0.9907 0.9080 0.8989 0.7705 0.7618
PLM1 0.9994 0.9988 0.9960 0.8604 0.8531 0.8809 0.8806
PLM2 0.9994 0.9988 0.9959 0.8607 0.8549 0.8794 0.8783
LE 0.9985 0.9892 0.9702 0.8165 0.8076 0.8213 0.8582
PL-LM 0.9920 0.9873 0.9744 0.8356 0.8227 0.8075 0.7480
PLW 0.9988 0.9859 0.9762 0.8473 0.8294 0.8795 0.8918
FC 0.9801 0.9713 0.9616 0.8006 0.8004 0.8871 0.8868
RMANOVA1 0.4838 0.4356 0.3864 0.7273 0.7066 0.1616 0.1319
RMANOVA2 0.7556 0.7712 0.6028 0.7867 0.7849 0.7468 0.6299
FIRSTP 0.9725 0.9611 0.9282 0.8500 0.8347 0.8135 0.8680
PUMA 0.9435 0.9276 0.9019 0.9133 0.9143 0.7901 0.7769
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Page 9 of 17NFM P-Value Calculation
Based on its consistently strong performance on the
spike-in data, including small-sample subsets, NFM was
applied to the motivating bovine NT data. To assess sta-
tistical significance in this application, p-values (with
subsequent multiple testing adjustment) are necessary.
T h eF - s t a t i s t i c sf r o mN F Mh a v eat h e o r e t i c a l
Fg ni i
g − − () = ∑ 1 1 1
, sampling distribution, where g is the
number of treatment levels and ni is the number of
samples within treatment level i. In other words, when
the null hypothesis H0: T1 = T2 is true, the F-statistics
will theoretically have this approximate distribution, and
p-values could be obtained as tail probabilities. The
validity of this distributional assumption can be assessed
using the F-statistics for the non-spiked-in genes in the
three spike-in datasets, because the null hypothesis is
known to be true for these genes.
The F-quantile plots in Figure 9 summarize this distri-
butional assumption assessment. The 4 × 4 HGU95A
comparison (Figure 9a) is the only case where the
Figure 5 Partial ROC curves for GCRMA-preprocessed data. (a-h) Partial ROC curves from Figure 4 to focus on portions of greatest interest -
low false positive and high true positive rates. Note that the vertical axes in (f) and (g) are on the log scale to facilitate visualization. The same
color legend of Figure 4 applies here.
Stevens et al. BMC Bioinformatics 2010, 11:281
http://www.biomedcentral.com/1471-2105/11/281
Page 10 of 17theoretical distribution is reasonably close to the
observed distribution. The 3 × 3 Golden Spike compari-
son (Figure 9f) is the only case where the observed dis-
tribution is longer-tailed than the theoretical
distribution. In all other cases, the distributions of the
observed F-statistics are grossly short-tailed compared
to the theoretical sampling distributions. This will affect
p-value calculations, as the tail probabilities (p-values)
from these theoretical sampling distributions will not be
small enough to allow claims of statistical significance,
even for these spike-in datasets.
An alternative sampling distribution is generated by a
permutation approach. Existing permutation or bootstrap
approaches permute or resample treatment labels, and
the p-value for each gene is the proportion of all resam-
ples producing a test statistic for the gene at least as
extreme as the original test statistic for the gene. An
implementation of such an approach [30] is found in the
Figure 6 ROC curves for Golden Spike data, by known fold chang. With RMA preprocessing, the performance of several methods testing for
differential expression is compared using the full 3 × 3 comparison of the Golden Spike spike-in data, treating the eight levels of reported
spiked-in fold changes separately. Several methods have difficulty detecting differential expression for spiked-in genes with fold changes 1.5 and
1.7 in particular.
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Page 11 of 17Figure 7 Rank of test statistics in Golden Spike data, by fold change. (a-e) With RMA preprocessing in the full 3 × 3 comparison of the
Golden Spike spike-in data, the overall ranks of test statistics from five methods are compared to the spiked-in fold changes. (The known fold
change of 1 corresponds to non-spiked-in genes.) Both PLLM and PUMA show an overall drop in ranks for higher fold changes, while
RMANOVA, NFM, and PLW show an overall increase in ranks for higher fold changes. There is a clear overall drop in NFM and PLW ranks for
spiked-in genes with fold changes 1.5 and 1.7. (f) With RMA preprocessing in the same Golden Spike comparison, the distributions of estimated
log fold changes are compared to the known spiked-in fold changes. There is a clear drop in estimated log fold changes for spiked-in genes
with known fold changes 1.5 and 1.7. This contributes to the poorer performance of the fold-change-based methods at these fold change levels.
Figure 8 Comparison of results on Bovine NT data. (a) The relationships among the methods considered here are visualized by clustering
the vectors of test statistic ranks within each method when applied to the bovine NT data. (b) A biplot (based on the first two principal
components of ranks of test statistics within method) visualizes the same relationships. The principal components were shifted for visualization
purposes, to allow both axes to be on the log scale.
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Page 12 of 17R package multtest [31]. Using this existing approach, the
smallest p-value possible will be the inverse of the num-
ber of resamples. For this reason, such a per-gene permu-
tation-based approach with very small sample sizes (as in
the current application) will not yield small enough p-
values to claim statistical significance, because the num-
ber of possible permutations is low.
For example, in the HGU133A dataset, there are 3
“control” and 3 “treatment” arrays under consideration,
so there are 6!/(3!·3!) = 20 possible permutations of
treatment labels. Due to the one-sided nature of the
NFM test statistic, there are actually only half that num-
ber of permutations that will give unique (or non-redun-
dant) test statistics for any given gene. For example, the
treatment labels (C,C,C,T,T,T) and (T,T,T,C,C,C) will
produce identical F-statistics for a given gene, where C
represents control and T represents treatment. Then the
smallest p-value using this per-gene permutation
Figure 9 F-quantile plots of the NFM test statistics of non-spike-in genes. Quantile plots for the HGU95A, HGU133A, and Golden Spike
datasets show that the theoretical F-distribution (vertical axis) is not a good approximation for the sampling distribution of the observed NFM
test statistics (horizontal axis). A solid black curve represents the quantile plot for the test statistics of the non-spike-in genes in each full data
and subset comparison. Deviations from the dashed red reference line of equality indicate departures from the theoretical distribution.
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Page 13 of 17approach is 1/10, and no claims of significance can be
made, particularly after adjusting for multiple hypothesis
testing.
Instead, we propose to use the same sampling distri-
bution for the test statistics of all genes in an experi-
ment. If the Fg ni i
g − − () = ∑ 1 1 1
, distribution had been a
good approximation for the sampling distribution of the
NFM test statistics for which the null hypothesis was
known to be true, then that same theoretical distribu-
tion would have been used for the p-value calculation of
all genes in the experiment. Since this theoretical distri-
bution was shown to be a poor approximation (Figure
9), we generate an alternative, more appropriate distri-
bution using permutations.
For a given experiment, we enumerate all treatment
label permutations, and for each permutation we calcu-
late the NFM test statistic for each gene. Our sampling
distribution is the collection of test statistics for all
genes across all permutations of treatment labels. Then
for each gene, the NFM p-value is the proportion of all
test statistics in this collection that are at least as
extreme (large) as the gene’s test statistic using the ori-
ginal treatment labels. The false discovery rate [32] is
controlled by converting these raw p-values to q-values
using the R package qvalue [33].
Figure 10 summarizes the significance results for the
three spike-in datasets, using the full comparison (4 × 4
or 3 × 3) for each. As the number of spike-in genes
increases (14 in HGU95A, 45 in HGU133A, 1,331 in
Golden Spike), the distribution of NFM permutation p-
values becomes less uniform (Figure 10a-c). For the
HGU95A and HGU133A datasets, statistical significance
(q-value <0.1) is more common for spike-in genes with
higher control and treatment concentrations (Figure
10d-e). These concentrations are as reported by the
dataset publisher [6]. The only notable exception is the
407_at probeset in the HGU95A dataset, represented by
a large open circle in the upper-right of Figure 10d. For
this probeset, the control concentration is 512 pM,
the treatment concentration is 1024 pM, and the NFM
Figure 10 Significance plots of NFM permutation results. (a-c) Histograms of NFM permutation p-values for the full data comparisons in
each of the three spike-in datasets. (d-e) Bubble plots for the spike-in genes of the HGU95A and HGU133A spike-in datasets. The horizontal and
vertical axes are the spike-in concentrations for the control and treatment conditions, with axis tick marks on the log scale. The size of the
plotting character for each spike-in gene is proportional to the corresponding q-value (converted from NFM permutation p-values). Q-values less
than 0.1 are represented as closed blue dots, while q-values greater than 0.1 are represented as open circles. Statistical significance (q-value <
0.1) is more common for genes with higher control and treatment concentrations. (f) The distribution of calculated NFM q-values (converted
from NFM permutation p-values) by spiked-in fold-change for the spike-in genes of the Golden Spike dataset.
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Page 14 of 17q - v a l u ei s0 . 4 3 .T h ed a t a s e tpublisher reports that cer-
tain probe pairs for this 407_at probeset have been
found to perform poorly [6], which may explain this
anomalous result. For the Golden Spike dataset, the
spike-in genes’ q-values tend to be small (Figure 10f),
except for the aforementioned known fold-change values
of 1.5 and 1.7, where the estimated log fold-changes
were quite small (Figure 7f).
NFM Convergence
The iterative REML process used by the NFM method
to obtain test statistics can converge slowly, and for
some genes it does not by default converge in R. How-
ever, model convergence for these same genes in SAS
[34] is not problematic. We have found that the non-
convergence in R can be eliminated by trivial rounding
of the log-scale intensity data (to the fifth decimal place,
for example).
NFM Bovine NT Application
In applying the NFM method to the motivating bovine
NT data, we used a non-specific filter [35,36], and only
calculated q-values for the 16,706 genes with expression
above 20 on at least two of the seven arrays. With RMA
preprocessing, this resulted in 584 significant genes
(FDR .05). As a check for biological relevance, we then
tested for over-representation of biological process Gene
Ontology terms [37] using a conditional hypergeometric
test [38,39].
The clone samples in these motivating bovine NT data
were the result of somatic cell nuclear transfer (SCNT).
Despite improvements in recent years, bovine somatic
cell nuclear transfer efficiency remains quite low. While
pregnancy rates of transferred SCNT embryos approach
those of transferred in vitro fertilized (IVF) embryos,
pregnancy loss throughout gestation, and particularly in
the first trimester, is much higher for SCNT pregnan-
cies. The placental structure in SCNT pregnancies is
often remarkably different in bovine SCNT pregnancies,
with significantly fewer and significantly larger cotyle-
dons and caruncles [40]. In addition, SCNT fetuses that
are lost mid-gestation as well as a portion of those that
reach term demonstrate developmental abnormalities
and metabolic problems [41-43].
An evaluation of the most significantly over-repre-
sented biological processes (from the conditional hyper-
geometric test) provides interesting insight regarding
aberrations in SCNT cotyledons. Three main categories
of over-represented biological processes were identified
- cell cycle regulation, metabolism, and early develop-
mental processes. Cell cycle arrest was the most signifi-
cantly over-represented biological process. The most
significantly over-represented metabolism ontologies
were RNA processing and sphingolipid metabolic pro-
cess. Among the most significantly over-represented
developmental processes were brain development,
neuron maturation, hindlimb morphogenesis, in utero
embryonic development, and muscle organ develop-
ment. These all fit very well with the abnormal pheno-
types we see in SCNT pregnancies.
Conclusion
Of the statistical methods considered here for small-
sample gene expression data, none was shown to be
consistently superior, but a few interesting conclusions
can be made. The fold-change-based methods (NFM,
PLM, LE, PLW, FC, and FIRSTP) tended to be more
consistent in their performance and provided the
expected increase in test statistic ranks for higher fold-
changes. By contrast, the non-fold-change-based meth-
ods (PLLM, RMANOVA, and PUMA) tended to be
more variable in performance, and two of them (PLLM
and PUMA) showed an unexpected decrease in test sta-
tistic ranks for higher fold-changes.
For small-sample gene expression experiments, the
nested factorial model (NFM) was shown to be a com-
petitive statistical approach for identifying differentially
expressed genes, particularly at low false positive rates.
The NFM method uses a permutation approach to cal-
culate a p-value for each gene. These permutations add
computational expense, but this expense must be taken
in perspective. Small-sample studies (for which NFM is
of immediate interest) are common in applications
where physical samples are either scarce or prohibitively
expensive. When a research team is unable to acquire
additional biological samples or chips to perform a lar-
ger-sample gene expression study, they will have to
compensate with additional waiting time. For the
HGU95A spike-in dataset, with 12,626 genes on 4 con-
trol and 4 treatment arrays, the total runtime to acquire
the permutation p-values was about 38 hours on a typi-
cal desktop PC. The HGU133A spike-in dataset, with
22,300 genes on 3 control and 3 treatment arrays,
required a runtime of about 16 hours. The Golden
Spike spike-in dataset, with 14,010 genes on 3 control
and 3 treatment arrays, required a runtime of about 10
hours. The runtime for the bovine NT dataset, with
24,128 genes on 3 control and 4 treatment arrays, was
about 50 hours. When a research team faces insufficient
resources for a larger-sample gene expression study,
these runtimes should not seem particularly onerous.
The NFM methodology described here, including the
p-value permutation approach and trivial rounding in
cases of initial non-convergence, has been implemented
in R code (affyNFM) freely available from the first
author’s website at http://www.stat.usu.edu/~jrstevens. A
tutorial document (including a reproducible example) is
provided on the same website.
We conclude with a caveat for those who may attempt
too much analysis with too little data. The development
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Page 15 of 17and availability of statistical methodology specifically for
small-sample gene expression studies (such as the NFM
here) should not be taken as encouragement of poor
design. Our motivating example involved data where it
was extremely expensive to obtain a single biological
sample (of the clone). In practice, we would have pre-
ferred a larger sample size to provide more information
on population-level biological variability. It was not
merely expensive to acquire the chips, and not merely
inconvenient to acquire additional biological replicates.
We emphasize that sufficient sample size for useful
inference should remain a guiding principle of experi-
mental design in gene expression studies.
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